June 30, 2026 | Labcorp announced the nationwide availability of ColoSense; Hartwig Medical Foundation and Ultima Genomics announce an expansion of their strategic collaboration; the University of Texas MD Anderson Cancer Center join a global consortium dedicated to eliminating cervical cancer worldwide; and more.
NVIDIA announced NVIDIA BioNeMo Agent Toolkit, which provides domain-specific tools and skills for the agentic life sciences era. Including more than a decade’s worth of NVIDIA life sciences libraries, tools and open models, the toolkit enables AI agents, scientists and labs to work together by gathering evidence, reasoning across findings, running computational experiments and recommending the next best steps to accelerate discovery. It gives any agent or AI platform — from general-purpose assistants to specialized scientific agents, software platforms and in-house biopharma systems — the tools needed to synthesize and summarize scientific knowledge, call models, evaluate results, reason and execute next actions. Press release.
Sanofi has inked a partnership deal with Pangaea Data to use its AI platform that helps detect Alpha-1 Antitrypsin Deficiency (AATD), which will be distributed to select healthcare systems and low-income community care clinics. The platform scours patient records — even unstructured data like clinical notes — to uncover actionable information that clinicians and providers can use to determine whether a patient may need additional clinical evaluation. Press release.
Labcorp announced the nationwide availability of ColoSense. ColoSense is designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling. It uses RNA-based technology to detect biomarkers associated with both colorectal cancer and advanced adenomas, precancerous changes that may be an early indication of disease. Once ordered, the collection kit is delivered directly to the consumer's home for collection and return, featuring a simplified design that eliminates the need to separate or mix the stool sample. Press release.
TETmedical announced that the FDA has granted Breakthrough Device Designation to its Neuron Specific Enolase — Functional Activity Stroke Test (NSE-FAST), a rapid in vitro diagnostic assay intended to aid in the diagnosis of acute ischemic stroke. NSE-FAST is a rapid, enzyme-based luminescence assay that measures the functional enzymatic activity of neuron-specific enolase in a patient’s blood plasma. The test is intended for use in conjunction with other available clinical information. The NSE-FAST utilizes TETmedical’s patented Tethered Enzyme Technology to rapidly measure NSE functional activity as a biomarker for acute ischemic stroke. Press release.
10x Genomics announced a research collaboration with Cleveland Clinic to advance research in novel diagnostics for bladder cancer. The multi-year collaboration intends to initially examine tumor samples from patients with advanced bladder cancer undergoing emerging therapeutic regimens using 10x's Flex Apex and Xenium platforms, with the goal of expanding to the recently announced Atera platform. The research aims to identify clinically relevant biomarkers that may help predict bladder cancer patient response to treatment and support future diagnostic development across tumor types. Press release.
Hartwig Medical Foundation and Ultima Genomics expanded their strategic collaboration, marked by Hartwig's adoption of the new Ultima UG200, Ultima's second-generation sequencing system. The agreement builds on the organization's existing work with Ultima's technology and is designed to accelerate Hartwig's mission to make whole-genome sequencing more accessible, scalable, and clinically actionable for oncology patients. Press release.
The University of Texas MD Anderson Cancer Center joined a global consortium dedicated to accelerating the elimination of cervical cancer worldwide. The collaboration agreement with the Elimination Partnership in Cervical Cancer (EPICC) expands UT MD Anderson’s global oncology efforts, further strengthening its commitment to advancing cancer prevention and control in medically underserved regions. The EPICC program, led by the University of Sydney in collaboration with a consortium of local and global partners, is funded by the Australian Government and the Minderoo Foundation. The initiative works to improve sustainable health outcomes and equity and to support national cervical cancer elimination strategies around the world. The program provides a mix of technical, policy, and implementation support for vaccination, screening, and treatment in more than nine countries. Press release.
AOA Dx announced its AKRIVIS GD multi-omic blood test achieved 92% sensitivity for early-stage ovarian cancer detection in symptomatic women, nearly double the sensitivity historically associated with CA-125, the current standard biomarker for ovarian cancer detection. The findings mark a major milestone in cancer diagnostics: the first successful translation of lipid-based biomarkers into a clinically deployable cancer detection assay. By integrating lipid, protein, and metabolite signatures with machine learning, AOA Dx has built a multi-omic discovery engine designed to capture the complexity of disease progression, creating a platform with applications that extend far beyond a single cancer indication. Press release.
QIAGEN announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak. The assays are designed for use with the QIAcuity digital PCR system and are intended to help qualified laboratories evaluate emerging pathogen targets in research, wastewater surveillance, and other environmental monitoring settings. The assays target the nucleoprotein and VP35 regions of the virus. Initial in silico sequence analysis showed no mismatches against the currently published outbreak sequences reviewed by QIAGEN. Press release.